Sarinnapha Vasunilashorn, Ph.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Delirium | 23 | 2022 | 1418 | 5.230 |
Why?
|
| C-Reactive Protein | 11 | 2021 | 3691 | 1.640 |
Why?
|
| Apolipoproteins E | 5 | 2020 | 1462 | 1.480 |
Why?
|
| Confusion | 2 | 2020 | 261 | 1.230 |
Why?
|
| Postoperative Complications | 16 | 2021 | 15035 | 1.220 |
Why?
|
| Psychometrics | 4 | 2022 | 3013 | 0.910 |
Why?
|
| Indians, South American | 2 | 2011 | 44 | 0.850 |
Why?
|
| Geriatric Assessment | 3 | 2020 | 1308 | 0.800 |
Why?
|
| Mobility Limitation | 3 | 2014 | 397 | 0.740 |
Why?
|
| Taiwan | 7 | 2018 | 488 | 0.710 |
Why?
|
| Activities of Daily Living | 5 | 2014 | 2317 | 0.680 |
Why?
|
| Epistasis, Genetic | 1 | 2020 | 375 | 0.640 |
Why?
|
| Inflammation | 7 | 2021 | 9948 | 0.630 |
Why?
|
| Severity of Illness Index | 8 | 2020 | 16161 | 0.630 |
Why?
|
| Catechol O-Methyltransferase | 1 | 2018 | 249 | 0.610 |
Why?
|
| Apolipoprotein E4 | 2 | 2020 | 610 | 0.580 |
Why?
|
| Stress, Psychological | 4 | 2014 | 4192 | 0.550 |
Why?
|
| Apolipoprotein E2 | 1 | 2015 | 131 | 0.550 |
Why?
|
| Blood-Brain Barrier | 1 | 2021 | 989 | 0.540 |
Why?
|
| Walking | 2 | 2013 | 1098 | 0.520 |
Why?
|
| Cytokines | 3 | 2019 | 7214 | 0.500 |
Why?
|
| Widowhood | 1 | 2013 | 50 | 0.500 |
Why?
|
| Disability Evaluation | 2 | 2013 | 1833 | 0.500 |
Why?
|
| Aged | 41 | 2022 | 162592 | 0.480 |
Why?
|
| Interview, Psychological | 1 | 2016 | 867 | 0.470 |
Why?
|
| Metabolism | 1 | 2014 | 213 | 0.460 |
Why?
|
| Marriage | 1 | 2013 | 312 | 0.450 |
Why?
|
| Aged, 80 and over | 22 | 2022 | 58752 | 0.440 |
Why?
|
| Body Weight | 2 | 2013 | 4720 | 0.440 |
Why?
|
| Nutrition Surveys | 4 | 2021 | 1548 | 0.440 |
Why?
|
| Psychiatric Status Rating Scales | 2 | 2020 | 6420 | 0.430 |
Why?
|
| Health Status | 3 | 2014 | 4027 | 0.430 |
Why?
|
| Anabolic Agents | 1 | 2014 | 250 | 0.420 |
Why?
|
| Wisconsin | 3 | 2016 | 125 | 0.400 |
Why?
|
| Parasitic Diseases | 1 | 2010 | 77 | 0.400 |
Why?
|
| Proteomics | 3 | 2021 | 3226 | 0.390 |
Why?
|
| Lipids | 3 | 2011 | 3233 | 0.380 |
Why?
|
| Aging | 6 | 2021 | 8309 | 0.360 |
Why?
|
| Life Change Events | 1 | 2014 | 947 | 0.360 |
Why?
|
| Telomere | 1 | 2014 | 823 | 0.340 |
Why?
|
| Female | 48 | 2022 | 377269 | 0.330 |
Why?
|
| Interleukin-6 | 3 | 2022 | 3192 | 0.330 |
Why?
|
| Male | 44 | 2021 | 351848 | 0.310 |
Why?
|
| Disabled Persons | 2 | 2013 | 1150 | 0.300 |
Why?
|
| Perception | 1 | 2013 | 1180 | 0.300 |
Why?
|
| Prospective Studies | 13 | 2022 | 50734 | 0.300 |
Why?
|
| Stress, Physiological | 1 | 2014 | 1432 | 0.290 |
Why?
|
| Mental Health | 2 | 2016 | 2568 | 0.280 |
Why?
|
| Longitudinal Studies | 9 | 2018 | 13595 | 0.280 |
Why?
|
| Body Mass Index | 5 | 2016 | 12426 | 0.270 |
Why?
|
| Morbidity | 1 | 2010 | 1694 | 0.260 |
Why?
|
| Inflammation Mediators | 1 | 2013 | 1956 | 0.260 |
Why?
|
| Health Status Indicators | 1 | 2010 | 993 | 0.250 |
Why?
|
| Humans | 54 | 2022 | 709431 | 0.250 |
Why?
|
| Postural Balance | 1 | 2009 | 633 | 0.250 |
Why?
|
| Health Surveys | 2 | 2011 | 4032 | 0.250 |
Why?
|
| Vision Disorders | 1 | 2011 | 1031 | 0.250 |
Why?
|
| Communicable Diseases | 1 | 2011 | 801 | 0.240 |
Why?
|
| Lung Diseases, Interstitial | 3 | 2011 | 735 | 0.230 |
Why?
|
| Depressive Disorder | 1 | 2016 | 3886 | 0.230 |
Why?
|
| Reproducibility of Results | 5 | 2022 | 19470 | 0.230 |
Why?
|
| Logistic Models | 7 | 2020 | 13622 | 0.230 |
Why?
|
| Cyclophosphamide | 3 | 2011 | 2195 | 0.220 |
Why?
|
| Bolivia | 2 | 2011 | 19 | 0.210 |
Why?
|
| Least-Squares Analysis | 2 | 2013 | 387 | 0.210 |
Why?
|
| Proteome | 2 | 2022 | 1747 | 0.210 |
Why?
|
| Sex Factors | 5 | 2016 | 10744 | 0.210 |
Why?
|
| Hospitalization | 2 | 2020 | 9632 | 0.200 |
Why?
|
| Osmolar Concentration | 1 | 2021 | 712 | 0.200 |
Why?
|
| Odds Ratio | 4 | 2016 | 10019 | 0.190 |
Why?
|
| Urine | 1 | 2021 | 389 | 0.190 |
Why?
|
| Italy | 2 | 2013 | 820 | 0.190 |
Why?
|
| Scleroderma, Diffuse | 2 | 2008 | 17 | 0.180 |
Why?
|
| Genetic Predisposition to Disease | 2 | 2018 | 17347 | 0.170 |
Why?
|
| Neurofilament Proteins | 1 | 2020 | 346 | 0.170 |
Why?
|
| Genotype | 4 | 2020 | 12955 | 0.170 |
Why?
|
| Mortality | 1 | 2010 | 2794 | 0.170 |
Why?
|
| Scleroderma, Systemic | 1 | 2011 | 295 | 0.170 |
Why?
|
| Case-Control Studies | 6 | 2022 | 21874 | 0.170 |
Why?
|
| Alleles | 3 | 2020 | 7123 | 0.170 |
Why?
|
| Cognitive Reserve | 1 | 2017 | 67 | 0.160 |
Why?
|
| Follow-Up Studies | 6 | 2019 | 39394 | 0.160 |
Why?
|
| Albuminuria | 1 | 2021 | 674 | 0.160 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 3 | 2021 | 4012 | 0.160 |
Why?
|
| Risk Factors | 10 | 2019 | 70264 | 0.150 |
Why?
|
| Incidence | 5 | 2020 | 20587 | 0.150 |
Why?
|
| Area Under Curve | 1 | 2020 | 1694 | 0.140 |
Why?
|
| National Institute on Aging (U.S.) | 1 | 2015 | 31 | 0.140 |
Why?
|
| Age Factors | 4 | 2016 | 18954 | 0.140 |
Why?
|
| Socioeconomic Factors | 3 | 2016 | 7740 | 0.140 |
Why?
|
| Glomerular Filtration Rate | 1 | 2021 | 2098 | 0.120 |
Why?
|
| Respiratory Function Tests | 2 | 2013 | 1667 | 0.120 |
Why?
|
| Orthopedic Procedures | 2 | 2021 | 1262 | 0.120 |
Why?
|
| Middle Aged | 15 | 2021 | 215428 | 0.120 |
Why?
|
| Diet | 1 | 2011 | 7505 | 0.120 |
Why?
|
| ROC Curve | 1 | 2020 | 3537 | 0.110 |
Why?
|
| Risk Assessment | 4 | 2017 | 23519 | 0.110 |
Why?
|
| England | 1 | 2013 | 517 | 0.110 |
Why?
|
| Cohort Studies | 7 | 2021 | 39650 | 0.110 |
Why?
|
| Vitamin D Deficiency | 1 | 2021 | 1350 | 0.110 |
Why?
|
| Cultural Characteristics | 1 | 2013 | 263 | 0.110 |
Why?
|
| Antirheumatic Agents | 1 | 2011 | 1356 | 0.110 |
Why?
|
| Health Behavior | 2 | 2013 | 2590 | 0.110 |
Why?
|
| Polymorphism, Genetic | 2 | 2013 | 4385 | 0.100 |
Why?
|
| Spouses | 1 | 2013 | 277 | 0.100 |
Why?
|
| Geriatrics | 1 | 2015 | 371 | 0.100 |
Why?
|
| Obesity | 1 | 2013 | 12008 | 0.100 |
Why?
|
| Body Weights and Measures | 1 | 2010 | 217 | 0.100 |
Why?
|
| Waist Circumference | 1 | 2013 | 906 | 0.090 |
Why?
|
| Immunosuppressive Agents | 2 | 2011 | 4228 | 0.090 |
Why?
|
| Scleroderma, Localized | 1 | 2009 | 76 | 0.090 |
Why?
|
| Scleroderma, Limited | 1 | 2008 | 7 | 0.090 |
Why?
|
| Vision, Low | 1 | 2011 | 161 | 0.090 |
Why?
|
| Hospitals | 1 | 2022 | 3232 | 0.090 |
Why?
|
| Nursing Homes | 1 | 2016 | 958 | 0.090 |
Why?
|
| Leukocyte Count | 1 | 2013 | 1677 | 0.090 |
Why?
|
| Genetic Association Studies | 1 | 2018 | 2710 | 0.090 |
Why?
|
| Multivariate Analysis | 3 | 2017 | 12517 | 0.090 |
Why?
|
| Neuropsychological Tests | 2 | 2020 | 6969 | 0.090 |
Why?
|
| Sex Ratio | 1 | 2008 | 104 | 0.080 |
Why?
|
| Homocysteine | 1 | 2011 | 656 | 0.080 |
Why?
|
| Length of Stay | 2 | 2021 | 6273 | 0.080 |
Why?
|
| Sampling Studies | 1 | 2009 | 648 | 0.080 |
Why?
|
| Occupations | 1 | 2009 | 510 | 0.080 |
Why?
|
| Blindness | 1 | 2011 | 589 | 0.080 |
Why?
|
| Prognosis | 3 | 2021 | 29148 | 0.080 |
Why?
|
| Tomography, X-Ray Computed | 4 | 2020 | 20307 | 0.070 |
Why?
|
| Risk | 2 | 2017 | 9813 | 0.070 |
Why?
|
| Educational Status | 1 | 2013 | 2327 | 0.070 |
Why?
|
| Blood Pressure | 2 | 2013 | 8512 | 0.070 |
Why?
|
| Kidney | 1 | 2021 | 6872 | 0.070 |
Why?
|
| Dementia | 2 | 2017 | 2211 | 0.070 |
Why?
|
| Forecasting | 1 | 2015 | 2957 | 0.070 |
Why?
|
| Alzheimer Disease | 2 | 2017 | 7097 | 0.070 |
Why?
|
| Risk-Taking | 1 | 2011 | 986 | 0.070 |
Why?
|
| Frail Elderly | 1 | 2010 | 592 | 0.070 |
Why?
|
| Longevity | 1 | 2013 | 1014 | 0.070 |
Why?
|
| Prevalence | 3 | 2021 | 14849 | 0.070 |
Why?
|
| Exercise | 1 | 2021 | 5269 | 0.070 |
Why?
|
| Cognition | 2 | 2020 | 5948 | 0.070 |
Why?
|
| Demography | 1 | 2010 | 1617 | 0.070 |
Why?
|
| Overweight | 1 | 2016 | 2212 | 0.070 |
Why?
|
| Reward | 1 | 2011 | 839 | 0.070 |
Why?
|
| Time Factors | 3 | 2016 | 41295 | 0.070 |
Why?
|
| Linear Models | 1 | 2015 | 6012 | 0.070 |
Why?
|
| Life Expectancy | 1 | 2011 | 1119 | 0.070 |
Why?
|
| Arteries | 1 | 2009 | 1129 | 0.060 |
Why?
|
| Sex Distribution | 1 | 2010 | 2379 | 0.060 |
Why?
|
| Vital Capacity | 2 | 2011 | 910 | 0.060 |
Why?
|
| Adolescent | 5 | 2021 | 85327 | 0.060 |
Why?
|
| Disease Progression | 2 | 2019 | 13298 | 0.060 |
Why?
|
| Exercise Tolerance | 1 | 2009 | 795 | 0.060 |
Why?
|
| Infant Mortality | 1 | 2008 | 746 | 0.060 |
Why?
|
| Adult | 10 | 2021 | 212298 | 0.060 |
Why?
|
| Infant, Newborn, Diseases | 1 | 2008 | 548 | 0.060 |
Why?
|
| United States | 4 | 2021 | 67177 | 0.060 |
Why?
|
| Societies, Medical | 1 | 2015 | 3665 | 0.060 |
Why?
|
| Confidence Intervals | 1 | 2009 | 3000 | 0.060 |
Why?
|
| Hypercholesterolemia | 1 | 2010 | 1163 | 0.060 |
Why?
|
| Weight Gain | 1 | 2013 | 2195 | 0.060 |
Why?
|
| Cholesterol | 1 | 2011 | 2857 | 0.060 |
Why?
|
| Patient Readmission | 1 | 2016 | 2947 | 0.060 |
Why?
|
| Hypertension | 2 | 2013 | 8150 | 0.060 |
Why?
|
| Lipid Metabolism | 1 | 2011 | 2009 | 0.050 |
Why?
|
| Life Style | 1 | 2013 | 3711 | 0.050 |
Why?
|
| Research Design | 1 | 2017 | 5860 | 0.050 |
Why?
|
| Sex Characteristics | 1 | 2011 | 2497 | 0.050 |
Why?
|
| Cerebral Cortex | 1 | 2017 | 5713 | 0.050 |
Why?
|
| Databases, Factual | 1 | 2016 | 7801 | 0.050 |
Why?
|
| Adiposity | 1 | 2009 | 1725 | 0.050 |
Why?
|
| Glial Fibrillary Acidic Protein | 1 | 2020 | 517 | 0.050 |
Why?
|
| Biomedical Research | 1 | 2015 | 3280 | 0.050 |
Why?
|
| Quality of Life | 2 | 2019 | 11553 | 0.050 |
Why?
|
| Anti-Infective Agents | 1 | 2005 | 928 | 0.040 |
Why?
|
| Proportional Hazards Models | 1 | 2013 | 12442 | 0.040 |
Why?
|
| Cognition Disorders | 1 | 2013 | 4010 | 0.040 |
Why?
|
| Calcinosis | 1 | 2006 | 1434 | 0.040 |
Why?
|
| Lung Diseases | 1 | 2008 | 1890 | 0.040 |
Why?
|
| Survival Analysis | 1 | 2011 | 10603 | 0.040 |
Why?
|
| Algorithms | 2 | 2016 | 13668 | 0.040 |
Why?
|
| Decision Making | 1 | 2011 | 3807 | 0.040 |
Why?
|
| Expert Testimony | 1 | 2019 | 357 | 0.040 |
Why?
|
| Cardiovascular Diseases | 2 | 2013 | 14054 | 0.040 |
Why?
|
| Sensitivity and Specificity | 2 | 2009 | 14895 | 0.040 |
Why?
|
| Predictive Value of Tests | 2 | 2009 | 15316 | 0.030 |
Why?
|
| Coronary Vessels | 1 | 2006 | 2941 | 0.030 |
Why?
|
| Chronic Disease | 1 | 2010 | 9011 | 0.030 |
Why?
|
| Depression | 1 | 2013 | 7201 | 0.030 |
Why?
|
| Calcium | 1 | 2006 | 5808 | 0.030 |
Why?
|
| Mass Spectrometry | 1 | 2021 | 2283 | 0.030 |
Why?
|
| Atrophy | 1 | 2017 | 1493 | 0.030 |
Why?
|
| Double-Blind Method | 2 | 2011 | 12008 | 0.030 |
Why?
|
| Metabolomics | 1 | 2021 | 1358 | 0.030 |
Why?
|
| Memory, Short-Term | 1 | 2018 | 944 | 0.030 |
Why?
|
| Games, Experimental | 1 | 2011 | 35 | 0.030 |
Why?
|
| Psychomotor Performance | 1 | 2020 | 1952 | 0.030 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2011 | 15548 | 0.030 |
Why?
|
| tau Proteins | 1 | 2020 | 1629 | 0.030 |
Why?
|
| Executive Function | 1 | 2018 | 1316 | 0.020 |
Why?
|
| Cross-Sectional Studies | 2 | 2021 | 22944 | 0.020 |
Why?
|
| Retrospective Studies | 2 | 2019 | 71151 | 0.020 |
Why?
|
| Pulmonary Diffusing Capacity | 1 | 2008 | 90 | 0.020 |
Why?
|
| Total Lung Capacity | 1 | 2008 | 152 | 0.020 |
Why?
|
| Renal Insufficiency, Chronic | 1 | 2021 | 1903 | 0.020 |
Why?
|
| Computational Biology | 1 | 2021 | 3584 | 0.020 |
Why?
|
| Child, Preschool | 1 | 2011 | 41195 | 0.020 |
Why?
|
| Caregivers | 1 | 2019 | 1894 | 0.020 |
Why?
|
| Pressure | 1 | 2011 | 1243 | 0.020 |
Why?
|
| Cold Temperature | 1 | 2011 | 786 | 0.020 |
Why?
|
| Vitamin D | 1 | 2021 | 3117 | 0.020 |
Why?
|
| Coronary Artery Disease | 1 | 2006 | 6137 | 0.020 |
Why?
|
| Catecholamines | 1 | 2008 | 392 | 0.020 |
Why?
|
| Saliva | 1 | 2011 | 794 | 0.020 |
Why?
|
| Arabinose | 1 | 2005 | 32 | 0.020 |
Why?
|
| Cardiovascular Physiological Phenomena | 1 | 2008 | 239 | 0.020 |
Why?
|
| Massachusetts | 1 | 2019 | 8754 | 0.020 |
Why?
|
| Yersinia pestis | 1 | 2005 | 43 | 0.020 |
Why?
|
| DNA Topoisomerases, Type I | 1 | 2005 | 101 | 0.020 |
Why?
|
| Spirometry | 1 | 2008 | 858 | 0.020 |
Why?
|
| Neoplasms | 1 | 2013 | 20421 | 0.020 |
Why?
|
| Comorbidity | 1 | 2019 | 10621 | 0.020 |
Why?
|
| Placebos | 1 | 2009 | 1773 | 0.020 |
Why?
|
| Brain | 1 | 2011 | 24936 | 0.020 |
Why?
|
| Etoposide | 1 | 2005 | 632 | 0.020 |
Why?
|
| Positron-Emission Tomography | 1 | 2020 | 6123 | 0.020 |
Why?
|
| Hydrocortisone | 1 | 2011 | 1727 | 0.020 |
Why?
|
| Catalysis | 1 | 2005 | 892 | 0.020 |
Why?
|
| Tryptophan | 1 | 2005 | 476 | 0.020 |
Why?
|
| Child | 1 | 2011 | 73998 | 0.010 |
Why?
|
| Amino Acid Motifs | 1 | 2005 | 977 | 0.010 |
Why?
|
| Electrophoresis, Polyacrylamide Gel | 1 | 2005 | 1961 | 0.010 |
Why?
|
| Radiography, Thoracic | 1 | 2009 | 1340 | 0.010 |
Why?
|
| Magnesium | 1 | 2005 | 853 | 0.010 |
Why?
|
| Mutagenesis, Site-Directed | 1 | 2005 | 1807 | 0.010 |
Why?
|
| Mutagenesis | 1 | 2005 | 1300 | 0.010 |
Why?
|
| Genetic Markers | 1 | 2008 | 2704 | 0.010 |
Why?
|
| Young Adult | 2 | 2021 | 56163 | 0.010 |
Why?
|
| Treatment Outcome | 2 | 2011 | 61963 | 0.010 |
Why?
|
| Plasmids | 1 | 2005 | 2516 | 0.010 |
Why?
|
| Oxygen | 1 | 2011 | 4148 | 0.010 |
Why?
|
| Protein Structure, Tertiary | 1 | 2005 | 4056 | 0.010 |
Why?
|
| Magnetic Resonance Imaging | 2 | 2017 | 34096 | 0.010 |
Why?
|
| Radiography | 1 | 2008 | 6993 | 0.010 |
Why?
|
| Binding Sites | 1 | 2005 | 6335 | 0.010 |
Why?
|
| Skin | 1 | 2009 | 4319 | 0.010 |
Why?
|
| Brain Mapping | 1 | 2011 | 6548 | 0.010 |
Why?
|
| Recombinant Proteins | 1 | 2005 | 6946 | 0.010 |
Why?
|
| Models, Molecular | 1 | 2005 | 5616 | 0.010 |
Why?
|
| Image Processing, Computer-Assisted | 1 | 2011 | 8971 | 0.010 |
Why?
|
| Escherichia coli | 1 | 2005 | 4402 | 0.010 |
Why?
|
| Amino Acid Sequence | 1 | 2005 | 14353 | 0.010 |
Why?
|
| Protein Binding | 1 | 2005 | 9694 | 0.010 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2005 | 11384 | 0.010 |
Why?
|
| Molecular Sequence Data | 1 | 2005 | 18883 | 0.010 |
Why?
|
| DNA | 1 | 2005 | 7276 | 0.010 |
Why?
|
| Infant, Newborn | 1 | 2008 | 24403 | 0.010 |
Why?
|
| Infant | 1 | 2008 | 34274 | 0.000 |
Why?
|
| Mutation | 1 | 2005 | 29242 | 0.000 |
Why?
|